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LETTER TO THE EDITOR
        The recent Perspectives on How to Drug an Ion Chan-
nel rightly point out the increasing relevance of ion 
channels as objects of therapy. We wish to add a few 
comments about the potential use of channel inhibitors 
in cancer therapy. During the last decade, different 
channel types have been found to be overexpressed in a 
variety of tumors, thus emerging as possible tumoral 
markers. What is more, ion channels often give mani-
fold contributions to the physiology of the neoplastic 
cell (  Kunzelmann, 2005  ). A generally recognized mech-
anism in proliferating cells, originally proposed for T 
lymphocyte activation, depends on interplay of K 
+   and 
Ca 
2+   channels (  DeCoursey et al., 1984  ). Ca 
2+   fl  uxes par-
ticipate in cell cycle control and K 
+   channels can modu-
late Ca 
2+   entry by regulating the resting V  m   (membrane 
potential). Ion channel engagement typically modulates 
other cellular processes, such as cell volume control and 
motility, which are implicated in cell division, migration, 
and invasiveness (e.g.,   Ransom et al., 2001  ). Malfunction 
of these is a hallmark of neoplastic progression and it 
is increasingly clear that ion channel effects can also be 
exerted by nonconductive signaling mechanisms (  Hegle 
et al. 2006  ). 
  Considering the pharmacological advantages they of-
fer, targeting ion channels would be a blessing for can-
cer therapy. When a given tumor specifi  cally expresses 
certain channel types, a possible strategy is local deliver-
ing of cytotoxic agents by means of compounds that 
bind these channels with high specifi  city, such as mono-
clonal antibodies or toxins (e.g., G  ó  mez-Varela et al., 
2007). However, direct antitumoral effects are also stud-
ied intensively, because many channel blockers are well 
known to inhibit cell proliferation in vitro. Although 
promising, the application of this strategy in vivo is still 
in its infancy. Besides the diffi  culty of fi  nding good lead 
molecules for medicinal chemistry developments, as 
discussed in the reviews of the present series, a serious 
drawback is that channel inhibitors can produce grave 
side effects. Here, we wish to comment about two issues 
that may offer ways to circumventing this problem. 
  The fi   rst point arises from the observations of 
  Kaczorowski et al., (2008)  , who suggest that, even when 
using compounds that are not specifi  c for channel iso-
forms, specifi  city of action can be achieved by exploit-
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ing the V  m   dynamics of different cell types. For example, 
neuropathic pain is believed to arise in damaged re-
gions that tend to produce local cell depolarization. 
Hence, Na 
+   channel blockers that tend to bind open 
and/or inactivated channels would address preferen-
tially depolarized or quickly fi  ring cells. This idea seems 
suggestive for oncologic applications as well, because 
the V  m  dynamics typical of proliferating cells is very dif-
ferent from that of excitable cells. An example from our 
fi  eld of research is K  V  11.1 (commonly named ERG1, from 
  ether-  à  -go-go   related gene type 1), whose contribution to 
the cardiac action potential repolarization is well estab-
lished. In brief, K  V  11.1 activates/inactivates at depolar-
ized potentials (typically, during the plateau of the 
cardiac action potential), but the inactivation is rapidly 
removed on repolarization, which lets ERG1 contribute 
to shape this phase. In fact, ERG1 inhibitors can pro-
duce serious arrhythmias. K  V  11.1 is often expressed in 
neoplastic cell lines and primary tumors (  Arcangeli, 2005  ), 
where it often seems to participate in the promotion 
of neoplastic progression. Its steady-state activation and 
  inactivation curves crossover around     40 mV (  Faravelli 
et al., 1996  ), thus producing a signifi  cant   “  window  ”   cur-
rent in the typical range of quasi-stationary V  m   of slowly 
cycling mammalian cells (between     30 and     50 mV, 
usually). Therefore, the proportion of channels residing 
in the different conformational states should be differ-
ent in excitable and proliferating cells, which we believe 
encourages to undertake a search for more state-specifi  c 
compounds, in order to achieve preferential targeting 
of neoplastic cells. An approach based on a similar rea-
soning could attempt to target specifi  c cell states. It has 
in fact been observed in different experimental systems 
that the K 
+   channel  ’  s voltage-dependent properties slowly 
oscillate in phase with the cell cycle stages (to the best 
of our knowledge, the fi  rst direct evidence was provided 
by   Day et al., 1993  ). 
  Second, as summarized by Andersen (2008), a drug 
can affect ion channels in different manners. It may ob-
struct the channel pore, or produce inhibition through 
binding of allosteric sites. In addition, an amphiphilic 
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compound has several potential ways of altering the 
channel  ’  s conformational states, by interacting with the 
lipid bilayer. To this list, we would add a further mecha-
nism that, aside from general physiological interest, may 
also turn out to allow a supplementary pharmacological 
strategy. Ion channels are increasingly recognized to as-
sociate with other membrane proteins to form macromo-
lecular complexes that modulate intracellular pathways. 
An example with implications for oncology is the interac-
tion between integrin receptors and ion channels. Work 
dating back to the early nineties (  Becchetti et al., 1992  ; 
  Schwartz, 1993  ) shows that integrin-mediated cell adhe-
sion to the extracellular matrix is often accompanied by 
ion channel activation, with ensuing effects on cell differ-
entiation, migration, and other aspects of developmental 
physiology sensu lato. More recent work indicates that 
these effects are often mediated by physical association 
between channel proteins and integrin receptors (e.g., 
  Levite et al., 2000  ). This association, besides reciprocal 
regulation between the proteins that form the complex, 
can recruit a variety of intracellular signaling elements 
and also feed back on either channel or integrin expres-
sion, or both (for review see   Arcangeli and Becchetti, 
2006  ). Therefore, we suggest that protein  –  protein inter-
actions are another possible target for drugs to alter the 
free energy difference between channel states. Among 
the extracellular pharmacological treatments (the most 
useful, in therapy), we deem that this tactic could offer 
another way to achieve tissue specifi  city. It may allow to 
address only those cell types in which certain receptors 
or accessory proteins are expressed. For instance, in hu-
man acute myeloid leukemia cells, hERG1 channels ap-
pear to mediate the vascular endothelial growth factor 
receptor-1  –  dependent cell migration and invasion, both 
in vitro and in vivo (  Pillozzi et al., 2007  ). In brief, the 
neoplastic cell clones expressing hERG1 tend to form a 
macromolecular complex between the growth factor re-
ceptor, the     1 integrin subunit, and the K 
+   channel itself. 
This process considerably increases the malignancy of tu-
mor cell populations. It should then be possible to fi  nd 
molecular strategies to disassemble such a multiprotein 
complex in malignant cells, which should produce little 
interference with the physiology of excitable cells. An-
other suggestive example that may be liable to both the 
above strategies is offered by voltage-gated Na 
+   channels, 
which mark late stages of breast and prostate cancer and 
whose accessory     1 subunit behaves as a cell adhesion 
molecule (  Brackenbury et al., 2008  ). 
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